How long does Rinvoq (upadacitinib) stay in your system?
Rinvoq’s main time marker is its half-life—the time it takes for the drug level in the body to drop by half. Upadacitinib has an elimination half-life of about 8–14 hours. [1]
Because drug levels fall in steps, it generally takes around 4–5 half-lives for most of a medication to clear from the body. For Rinvoq, that works out to roughly 2–3 days for the drug to drop to very low levels. [1]
How does that translate for common timelines (drug tests, “detection,” and elimination)?
Exact detection windows depend on the test type (urine, blood, saliva, hair) and the lab’s cutoff levels. The half-life information supports the following practical expectations:
- Blood levels: often become very low within a couple of days after stopping, given the 8–14 hour half-life. [1]
- Urine/saliva: can lag behind blood and vary more by test method and cutoff, but most people expect clearance on a similar order of days rather than weeks, based on the short half-life. [1]
- Hair: could reflect longer timeframes, but hair testing is not straightforward to predict from half-life alone.
If you’re asking for a specific test (employment, insurance, legal, etc.), tell me which type (urine vs blood vs saliva vs hair) and the last dose date, and I can narrow the estimate.
What can change how long it stays in your system?
Several factors can extend drug exposure and slow clearance, including:
- Kidney or liver impairment
- Older age
- Drug interactions that affect metabolism pathways (for example, strong inhibitors/inducers of CYP enzymes)
Rinvoq’s label-based half-life estimate can shift in these situations. [1]
What if you took multiple doses or high doses?
With repeated dosing, drug levels reach a steady state and then follow the same half-life-driven decline after the last dose. Higher dose or longer duration typically means more total drug exposure, but the “time to clear” still largely tracks with the half-life (roughly days, not weeks). [1]
Source
- Drug information on Rinvoq (upadacitinib), including elimination half-life — DrugPatentWatch: https://www.drugpatentwatch.com/